PT3180434T - Chamarizes oligonucleotídicos para o tratamento da dor - Google Patents

Chamarizes oligonucleotídicos para o tratamento da dor

Info

Publication number
PT3180434T
PT3180434T PT158320838T PT15832083T PT3180434T PT 3180434 T PT3180434 T PT 3180434T PT 158320838 T PT158320838 T PT 158320838T PT 15832083 T PT15832083 T PT 15832083T PT 3180434 T PT3180434 T PT 3180434T
Authority
PT
Portugal
Prior art keywords
pain
treatment
oligonucleotide decoys
decoys
oligonucleotide
Prior art date
Application number
PT158320838T
Other languages
English (en)
Portuguese (pt)
Inventor
Mamet Julien
Orr Rick
Manning Don
Harris Scott
Martin William
Original Assignee
Adynxx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adynxx Inc filed Critical Adynxx Inc
Publication of PT3180434T publication Critical patent/PT3180434T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/13—Decoys

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT158320838T 2014-08-15 2015-08-14 Chamarizes oligonucleotídicos para o tratamento da dor PT3180434T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462037996P 2014-08-15 2014-08-15

Publications (1)

Publication Number Publication Date
PT3180434T true PT3180434T (pt) 2019-10-29

Family

ID=55304669

Family Applications (1)

Application Number Title Priority Date Filing Date
PT158320838T PT3180434T (pt) 2014-08-15 2015-08-14 Chamarizes oligonucleotídicos para o tratamento da dor

Country Status (11)

Country Link
US (2) US10287583B2 (enExample)
EP (2) EP3180434B1 (enExample)
JP (2) JP6705807B2 (enExample)
CN (1) CN106661578B (enExample)
AU (1) AU2015301491A1 (enExample)
BR (1) BR112017002629A2 (enExample)
CA (1) CA2957250A1 (enExample)
ES (1) ES2750689T3 (enExample)
PT (1) PT3180434T (enExample)
RU (1) RU2017108238A (enExample)
WO (1) WO2016025829A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5646320B2 (ja) 2007-05-11 2014-12-24 アダイニクス， インコーポレイテッド 遺伝子発現と疼痛
RU2668136C2 (ru) 2012-05-10 2018-09-26 Эйдинкс, Инк. Композиции для доставки активных ингредиентов
CN106661578B (zh) 2014-08-15 2020-08-04 埃迪恩克斯股份有限公司 用于疼痛治疗的寡核苷酸诱饵
FR3029450B1 (fr) * 2014-12-03 2017-11-03 Pole De Plasturgie De Lest Dispositif de moulage pour la fabrication de pieces en materiau composite a partir de resine polymere liquide par injection haute pression.
US20220072026A1 (en) * 2018-12-24 2022-03-10 The Regents Of The University Of California Treatment of spinal conditions with chimera decoy
US12031134B2 (en) 2020-08-13 2024-07-09 Nevada Research & Innovation Corporation KLF11 siRNA for treatment of diabetes and obesity
US20250011787A1 (en) 2021-10-21 2025-01-09 The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glads Retroelement-generated transcription factor decoys

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150090A (en) 1986-01-09 2000-11-21 Massachusetts Institute Of Technology Nuclear factors associated with transcriptional regulation
US5206152A (en) 1988-04-08 1993-04-27 Arch Development Corporation Cloning and expression of early growth regulatory protein genes
DE3815221C2 (de) 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
KR100225087B1 (ko) 1990-03-23 1999-10-15 한스 발터라벤 피타아제의 식물내 발현
US5272056A (en) 1991-01-03 1993-12-21 The Research Foundation Of State University Of New York Modification of DNA and oligonucleotides using metal complexes of polyaza ligands
CA2106386A1 (en) 1991-04-18 1992-10-19 Barbara C. F. Chu Oligodeoxynucleotides and oligonucleotides useful as decoys for proteins which selectively bind to defined dna sequences
FR2675803B1 (fr) 1991-04-25 1996-09-06 Genset Sa Oligonucleotides fermes, antisens et sens et leurs applications.
AU659482B2 (en) 1991-06-28 1995-05-18 Massachusetts Institute Of Technology Localized oligonucleotide therapy
CA2168245A1 (en) 1993-07-29 1995-02-09 C. Anthony Hunt Polynucleotide decoys that inhibit mhc-ii expression and uses thereof
EP1350514A3 (en) 1993-10-29 2004-07-07 The Brigham And Women's Hospital, Inc. Therapeutic use of cis-element decoys in vivo
AU3881095A (en) 1994-11-17 1996-06-17 Taiho Pharmaceutical Co., Ltd. Double-stranded oligonucleotide and carcinostatic agent containing the same as active ingredient
AU5369396A (en) 1995-03-23 1996-10-08 Research Foundation Of The State University Of New York, The Rest protein and dna
ATE271128T1 (de) 1995-05-11 2004-07-15 Applied Research Systems Inhibitoren der il-6 aktivitaet
DE69636997T2 (de) 1995-05-12 2007-07-12 Anges MG Inc., Ibaraki HEILUNG UND VORBEUGUNG VON DURCH NF-kappaB VERURSACHTEN ERKRANKUNGEN
GB9515356D0 (en) 1995-07-26 1995-09-20 Medical Res Council Improvements in or relating to delivery of nucleic acid
US6265389B1 (en) 1995-08-31 2001-07-24 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of oligonucleotides
US6245747B1 (en) 1996-03-12 2001-06-12 The Board Of Regents Of The University Of Nebraska Targeted site specific antisense oligodeoxynucleotide delivery method
WO1997044064A2 (en) 1996-05-20 1997-11-27 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Oligonucleotides which specifically bind retroviral nucleocapsid proteins
US6022863A (en) 1996-05-21 2000-02-08 Yale University Regulation of gene expression
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ，インコーポレイティド 人工抗体ポリペプチド
EP1008352A4 (en) 1997-07-04 2005-03-16 Fujisawa Pharmaceutical Co Cerebrospinal PROTECTOR
JP3667047B2 (ja) 1997-09-12 2005-07-06 キヤノン株式会社 人工核酸およびその製造方法、デオキシリボフラノース化合物、リボフラノース化合物およびこれらの製造方法
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
WO1999018792A1 (en) 1997-10-10 1999-04-22 Johns Hopkins University Gene delivery compositions and methods
US6060310A (en) 1997-11-24 2000-05-09 The United States Of America As Represented By The Department Of Health And Human Services Transcription factor decoy and tumor growth inhibitor
JP2002508386A (ja) 1997-12-16 2002-03-19 ザ・ユニバーシティー・オブ・サスカチワン・テクノロジーズ・インコーポレーテッド 導電性金属含有核酸
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
DK1083934T3 (da) 1998-06-02 2003-12-01 Glaxo Group Ltd Genterapifremgangsmåder
US6818626B1 (en) 1998-07-17 2004-11-16 Mirus Corporation Chelating systems for use in the delivery of compounds to cells
US6867289B1 (en) 1998-10-26 2005-03-15 Board Of Regents, The University Of Texas Systems Thio-modified aptamer synthetic methods and compositions
US6008048A (en) 1998-12-04 1999-12-28 Isis Pharmaceuticals Inc. Antisense inhibition of EGR-1 expression
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US7160869B2 (en) 1998-12-16 2007-01-09 University Of Saskatchewan Biologically active metal-containing nucleic acids
DK1141366T3 (da) 1998-12-23 2007-04-02 Genentech Inc Transfektaconer omfattende calciumphosphat og en nukleinsyre
US6395029B1 (en) 1999-01-19 2002-05-28 The Children's Hospital Of Philadelphia Sustained delivery of polyionic bioactive agents
US6333408B1 (en) 1999-03-08 2001-12-25 Kureha Chemical Industry Co., Ltd. Oligonucleotides inhibitors of PAI-1 MRNA
FR2790955B1 (fr) 1999-03-19 2003-01-17 Assist Publ Hopitaux De Paris Utilisation d'oligonucleotides stabilises comme principe actif antitumoral
US6387620B1 (en) 1999-07-28 2002-05-14 Gilead Sciences, Inc. Transcription-free selex
US6599741B1 (en) 1999-09-14 2003-07-29 Avontec Gmbh Modulating transcription of genes in vascular cells
US6927027B2 (en) 1999-12-21 2005-08-09 Ingeneus Corporation Nucleic acid multiplex formation
US6969704B1 (en) 2000-08-25 2005-11-29 The Trustees Of Columbia University In The City Of New York Methods for suppressing early growth response—1protein (Egr-1) to reduce vascular injury in a subject
EP1332209B1 (en) 2000-09-08 2009-11-11 Universität Zürich Collections of repeat proteins comprising repeat modules
US6376190B1 (en) 2000-09-22 2002-04-23 Somalogic, Inc. Modified SELEX processes without purified protein
DE10049549A1 (de) * 2000-10-06 2002-05-02 Markus Hecker Modulation der Transkription pro-inflammatorischer Genprodukte
AU2002213198A1 (en) 2000-10-11 2002-04-22 Laura Kragie Composition and method of alleviating adverse side effects and/or enhancing efficacy of agents that inhibit aromatase
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JPWO2002041922A1 (ja) 2000-11-24 2004-03-25 丸山　弘樹 生体に導入された遺伝子の発現産物の活性を制御する方法
WO2002066071A2 (en) 2001-01-03 2002-08-29 Thomas Jefferson University Treatment of tissue fibrosis by blocking the sp1 transcription factor
US7060690B2 (en) 2001-01-22 2006-06-13 Genta Incorporated Methods and compositions for treating a cell-proliferative disorder using CRE decoy oligomers, BCL-2 antisense oligomers, and hybrid oligomers thereof
JP3778357B2 (ja) 2001-02-20 2006-05-24 アンジェスＭｇ株式会社 デコイを含む薬学的組成物およびその使用方法
WO2002070668A2 (en) 2001-03-06 2002-09-12 Sierra Sciences, Inc. Methods and compositions for modulating telomerase reverse transcriptase (tert) expression
US20030166555A1 (en) 2001-04-02 2003-09-04 Alberini Cristina M. Methods and compositions for regulating memory consolidation
JP4369662B2 (ja) 2001-04-26 2009-11-25 アビディア インコーポレイテッド 単量体ドメインのコンビナトリアルライブラリー
US20040175756A1 (en) 2001-04-26 2004-09-09 Avidia Research Institute Methods for using combinatorial libraries of monomer domains
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
EP1298141A1 (en) 2001-09-27 2003-04-02 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Interleukin-4 (IL-4) promoter sequences specifically interacting with IRF-1 and IRF-2
DE10148828B4 (de) 2001-10-04 2005-05-19 Avontec Gmbh Modulation der Expression STAT-1-abhängiger Gene
US6663880B1 (en) 2001-11-30 2003-12-16 Advanced Cardiovascular Systems, Inc. Permeabilizing reagents to increase drug delivery and a method of local delivery
MXPA04007124A (es) 2002-02-01 2004-10-29 Omeros Corp Composiciones y metodos para la inhibicion sistemica de la degradacion del cartilago.
US7244592B2 (en) 2002-03-07 2007-07-17 Dyax Corp. Ligand screening and discovery
CN1240439C (zh) 2002-03-28 2006-02-08 南京凯基生物科技发展有限公司 肿瘤基因开关药物
KR100874798B1 (ko) 2002-04-26 2008-12-19 이인규 전사시 ｄｎａ 결합부위를 포함하는 원형의 아령형 디코이올리고뉴클레오티드
DE10242319A1 (de) 2002-09-12 2004-03-25 Avontec Gmbh Funkionelle Korrektur der-786C/T-Varianz des humanen eNOS-Gens
KR20140148502A (ko) 2002-12-09 2014-12-31 아브락시스 바이오사이언스, 엘엘씨 약리학적 물질의 조성물 및 그 전달방법
DE10257421A1 (de) 2002-12-09 2004-07-08 Grünenthal GmbH Regulatorische Elemente im 5'-Bereich des VR1-Gens
US20050158733A1 (en) 2003-06-30 2005-07-21 Gerber David J. EGR genes as targets for the diagnosis and treatment of schizophrenia
WO2005027830A2 (en) 2003-09-12 2005-03-31 Virginia Commonwealth University Chimeric transcription factor decoy oligonucleotides
WO2005084180A2 (en) 2003-12-19 2005-09-15 University Of Cincinnati Polyamides and polyamide complexes for delivery of oligonucleotide decoys
JP2005336081A (ja) 2004-05-26 2005-12-08 Anges Mg Inc Ｎｒ２ｂ−ｎｍｄａ受容体の再発現抑制剤
US7482158B2 (en) 2004-07-01 2009-01-27 Mathison Brian H Composite polynucleic acid therapeutics
WO2006012625A2 (en) 2004-07-22 2006-02-02 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Stat3 decoy oligonucleotides and uses therefor
CA2583413A1 (en) 2004-09-21 2006-03-30 Anesiva, Inc. Delivery of polynucleotides
JP4991547B2 (ja) 2004-09-28 2012-08-01 クアーク・ファーマスーティカルス、インコーポレイテッド 脱毛症、急性腎不全および他の疾患の治療のためのオリゴリボヌクレオチドおよびその使用の方法
ATE509100T1 (de) 2004-10-22 2011-05-15 Anges Mg Inc Chimäre (doppel-) attrappe
US20060189564A1 (en) 2004-10-22 2006-08-24 Medtronic, Inc. Methods and sequences to suppress pro-inflamatory cytokine actions locally to treat pain
US7585848B2 (en) 2005-01-11 2009-09-08 Rush University Medical Center Methods and compositions for treating, inhibiting and reversing disorders of the intervertebral disc
US8268572B2 (en) 2005-03-04 2012-09-18 Dana-Farber Cancer Institute, Inc. Methods to identify inhibitors of Runx1-mediated expression of nociceptive receptors and ion channels
WO2008105959A2 (en) 2006-10-09 2008-09-04 Neurofluidics, Inc. Cerebrospinal fluid purification system
CN101686939B (zh) 2007-04-17 2013-03-27 巴克斯特国际公司 用于肺部投送的核酸微粒
AU2014201462B2 (en) * 2007-05-11 2016-09-29 Adynxx, Inc. Gene expression and pain
JP5646320B2 (ja) 2007-05-11 2014-12-24 アダイニクス， インコーポレイテッド 遺伝子発現と疼痛
GB0906130D0 (en) * 2008-10-03 2009-05-20 Procrata Biosystems Ltd Transcription factor decoys
WO2011029092A1 (en) * 2009-09-04 2011-03-10 University Of Miami Klf family members regulate intrinsic axon regeneration ability
JP5775581B2 (ja) 2010-08-20 2015-09-09 レプリコール インコーポレーティッド オリゴヌクレオチドキレート錯体
CA2839896A1 (en) 2011-06-21 2012-12-27 Alnylam Pharmaceuticals, Inc. Assays and methods for determining activity of a therapeutic agent in a subject
MY166036A (en) 2011-07-20 2018-05-21 Hospira Inc Methods of treating pain
RU2668136C2 (ru) * 2012-05-10 2018-09-26 Эйдинкс, Инк. Композиции для доставки активных ингредиентов
HUE054875T2 (hu) 2012-05-18 2021-10-28 Replicor Inc Oligonukleotid kelátkomplex-polipeptid készítmények és eljárások
CN106661578B (zh) 2014-08-15 2020-08-04 埃迪恩克斯股份有限公司 用于疼痛治疗的寡核苷酸诱饵
WO2017151644A1 (en) 2016-02-29 2017-09-08 Adynxx, Inc. Compositions and methods for pain amelioration via modification of gene expression
CA3091832A1 (en) 2018-02-23 2019-08-29 Adynxx Sub, Inc. Compositions and methods for pain amelioration in patient population that scores high on the pain catastrophizing scale

Also Published As

Publication number Publication date
BR112017002629A2 (pt) 2018-02-20
US20190276825A1 (en) 2019-09-12
US20170247694A1 (en) 2017-08-31
CN106661578A (zh) 2017-05-10
CA2957250A1 (en) 2016-02-18
US10287583B2 (en) 2019-05-14
JP2017529834A (ja) 2017-10-12
EP3180434A1 (en) 2017-06-21
WO2016025829A1 (en) 2016-02-18
US10683502B2 (en) 2020-06-16
RU2017108238A (ru) 2018-09-17
EP3180434B1 (en) 2019-07-17
EP3180434A4 (en) 2018-04-04
AU2015301491A1 (en) 2017-02-02
ES2750689T3 (es) 2020-03-26
EP3626822A1 (en) 2020-03-25
RU2017108238A3 (enExample) 2019-09-18
JP2020141688A (ja) 2020-09-10
CN106661578B (zh) 2020-08-04
JP6705807B2 (ja) 2020-06-03

Similar Documents

Publication Publication Date Title
IL256634A (en) Therapeutic oligonucleotides
IL250960A0 (en) Combined treatment of sinecriviroc for the treatment of leprosy
PT3212233T (pt) Terapia combinada para o tratamento de doenças
GB201403104D0 (en) Skin treatment device
PL3215219T3 (pl) System do zabiegów na skórze
EP3180434A4 (en) Oligonucleotide decoys for the treatment of pain
GB201412578D0 (en) Treatment of neurological diseases
ZA201705847B (en) Treatment of pain
IL266098A (en) Soil treatment
PL3329004T3 (pl) Terapeutyczne oligonukleotydy
GB201604658D0 (en) Treatment for pain
EP3277726A4 (en) Pain treatment
GB201412700D0 (en) Flexible treatment chamber
SG11201800356WA (en) Biological treatment device
GB201411027D0 (en) Treatment
GB201412010D0 (en) Treatment of hypertransaminasemia
GB201412411D0 (en) Treatment
GB201505205D0 (en) Treatment for pain
GB201504688D0 (en) Treatment for pain
GB201413330D0 (en) Agricultural treatment
GB201400839D0 (en) Agricultural treatment
GB201407396D0 (en) Confectionary treatment
SMT201900724T1 (it) Trattamento della sindrome da dolore parossistico estremo
GB201410702D0 (en) Skin treatment device
AU2015901216A0 (en) Pain treatment